Poor to modest agreement between rheumatoid arthritis response measures in clinical practice

Clinical and Experimental Rheumatology

Volumn 27, Issue 4, 2009, Pages 633-640

  Michaud, Kaleb ^a,b,g   Mikuls, T R ^a   Call, S E ^c   Reimold, A M ^d   Hooker, R ^d   Kerr, G S ^c   Richards, J S ^c,e   Caplan, L ^f   Cannon, G W ^c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NATIONAL DATA BANK FOR RHEUMATIC DISEASES   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g NEBRASKA MEDICAL CENTER   (United States)

Author keywords

ACR improvement criteria; Disease activity; Disease activity score; Outcome assessment; Rheumatoid arthritis

Indexed keywords

RHEUMATOID FACTOR;

AGED; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RATING SCALE; RHEUMATOID ARTHRITIS;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HEALTH STATUS; HOSPITALS, VETERANS; HUMANS; JOINTS; MALE; PAIN; PAIN MEASUREMENT; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 70350163827     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. SMOLEN JS, VAN DER HEIJDE DM, ST CLAIR EW et al.: Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006; 54: 702-710
2. GENOVESE MC, BATHON JM, MARTIN RW et al.: Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 1443-1450
3. WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45. (Pubitemid 36091645)
4. MAINI R, ST CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-1939.
5. MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-147 (Pubitemid 27306284)
6. ALETAHA D, NELL VP, STAMM T et al.: Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796-806.
7. SMOLEN JS, BREEDVELD FC, SCHIFF MH et al.: A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003; 42: 244-257
8. ALETAHA D, SMOLEN J: The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23 (Suppl. 39): S100-108.
9. MAKINEN H, KAUTIAINEN H, HANNONEN P et al.: Disease activity score 28 as an instrument to measure disease activity in patients with early rheumatoid arthritis. J Rheumatol 2007; 34: 1987-1991 (Pubitemid 47548199)
10. CALL SE, CIPHER D, HOOKER R et al.: Real-time assessment of disease activity in rheumatoid arthritis (RADARA): use of threshold criteria improves specificity of composite clinical outcome measures [abstract]. Arthritis Rheum 2007; 56 (Suppl.): S706.
11. MIKULS TR, KAZI S, CIPHER D et al.: The association of race and ethnicity with disease expression in male US veterans with rheumatoid arthritis. J Rheumatol 2007; 34: 1480-1484
12. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324
13. FELSON DT, ANDERSON JJ, BOERS M et al.: The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993; 36: 729-740
14. PINCUS T, SWEARINGEN C, WOLFE F: Toward a multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum 1999; 42: 2220-2230
15. PREVOO ML, VAN 'T HOF MA, KUPER HH, VAN LEEUWEN MA, VAN DE PUTTE LB, VAN RIEL PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-48
16. FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-735
17. FRANSEN J, VAN RIEL PL: The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005; 23 (Suppl. 39): S93-99.
18. ALETAHA D, SMOLEN JS, KVIEN TK: Definition of moderate and major response for disease activity indices in rheumatoid arthritis (RA). Ann Rheum Dis 2006; 65 (Suppl. II): 692.
19. PINCUS T, CHUNG C, SEGURADO OG, AMARA I, KOCH GG: An index of patient reported outcomes (PRO-Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J Rheumatol 2006; 33: 2146-2152
20. LANDIS JR, KOCH GG: The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174
21. SOLOMON DH, GABRIEL SE: Quality Measures 101: what every rheumatologist should know. Clin Exp Rheumatol 2007; 25 (Suppl. 47): 18-21.
22. SOKKA T, PINCUS T: Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum 2003; 48: 313-318
23. ALETAHA D, SMOLEN JS: The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol 2007; 21: 663-675
24. WOLFE F, MICHAUD K: Resistance of rheumatoid arthritis patients to changing therapy: Discordance between disease activity and patients' treatment choices. Arthritis Rheum 2007; 56: 2135-2142
25. National Center for Veterans Analysis and Statistics (http://www.va.gov/ vetdata/accessed Oct 2, 2008).
26. ALETAHA D, FUNOVITS J, SMOLEN JS: The importance of reporting disease activity states in rheumatoid arthritis clinical trials. Arthritis Rheum 2008; 58: 2622-2631
27. WOLFE F, MICHAUD K: The challenges of determining RA disease activity and remission in clinical practice. Nature Clinical Practice 2008; 4: 462-463